Navigation Links
Clinical trial for diabetic macular edema enrolling patients
Date:3/26/2010

NEW YORK, March 26, 2010 A Phase II clinical trial for a promising treatment for diabetic eye disease has begun enrolling participants.

The Juvenile Diabetes Research Foundation, a leader in setting the agenda for diabetes research worldwide, and The Wilmer Eye Institute of Johns Hopkins University announced today that the READ 3 Study (Ranibizumab for Edema of the mAcula in Diabetes Protocol 3 with High Dose Study) will evaluate the safety and efficacy of a injections of an antibody treatment in people with diabetic macular edema (DME).

DME is a major complication of diabetes and a leading cause of blindness in adults. In DME, leakage of fluid from the blood vessels in the eye causes the retina to swell, resulting in blurring and visual loss.

The READ-3 Study is a collaboration between JDRF and Johns Hopkins University, with funding support from Genentech, Inc. (a member of the Roche group), and involves 14 clinical centers across the U.S. that will collectively enroll some 100 patients. The Wilmer Eye Institute of Johns Hopkins University will serve as the Coordinating Center for the participating clinical sites, and the Retinal Imaging Research and Reading Center at Wilmer will serve as the Reading Center for the READ 3 Study.

READ-3 is a Phase 2 study designed to compare two different doses of the antibody treatment to determine if a higher dose is more effective in improving vision and decreasing retinal thickness; it will also determine if higher doses can reduce the frequency of subsequent treatments for DME.

After screening to confirm diabetic macular edema (and no other factors that would exclude someone from the study), the participants will receive either 1 or 2 doses of ranibizumab for six months, followed by a six-month follow up-period with the option for additional treatments. Participants must be at least 18 years of age and have macular edema as the result of diabetes. For additional study information and participation, please visit www.READ3.net or JDRF's Clinical Trials Connection at www.trials.jdrf.org.

Without treatment, diabetic macular edema can cause vision impairment, blurriness, or blindness. Therapies to free people from the devastating health burden of complications that can accompany diabetes, including diseases of the eye, nerves, and kidneys, are an important focus of JDRF research; in the last fiscal year, the foundation invested more than $22 million in research involving Complications Therapies.

About Ranibizumab and the READ Studies

The READ-3 Trial is the third READ study to test the effectiveness of ranibizumab as a treatment of diabetic eye disease.

Ranibizumab is an antibody designed to block a protein called vascular endothelial growth factor (VEGF), which is produced in excessive amounts in people with diabetes. VEGF causes leakage in the small blood vessels of the eye that can lead to vision loss and, eventually, blindness. In the READ-1 study, Dr. Quan Dong Nguyen, Dr. Peter Campochiaro, and colleagues at the Wilmer Eye Institute of Johns Hopkins University (under the JDRF collaboration) treated 10 patients who suffered from chronic diabetic macular edema. The trial participants received injections of the drug, with follow-up injections at one, two, four, and six months. The injections were well-tolerated and the results showed that ranibizumab significantly reduced macular swelling and improved vision.

In the READ-2 Study (a multi-center national trial also supported by JDRF) designed by Dr. Nguyen, Dr. Campochiaro, and Dr. Diana Do of the Wilmer Eye Institute, researchers from 14 clinical centers throughout the U.S. enrolled 126 patients to compared the effectiveness of ranibizumab versus conventional treatment laser photocoagulation therapy. The study results showed a significantly greater improvement in vision in patients treated with ranibizumab than those receiving laser surgery or a combination of both.

Dr. Nguyen, Dr. Campochiaro, Dr. Do, and 14 other clinician scientists from clinical centers in California, Florida, Hawaii, Illinois, Kansas, Maryland, Pennsylvania, South Dakota, and Texas designed the READ-3 Study.

Ranibizumab was approved by the U.S. Food and Drug Administration for the treatment of patients with a type of age-related macular degeneration in June 2006. In addition to the READ studies, Genentech is conducting two parallel, phase 3 trials studying the safety and efficacy of different doses of ranibizumab to treat diabetic macular edema.


'/>"/>

Contact: Joana Casas
mcasas@jdrf.org
212-479-7560
Juvenile Diabetes Research Foundation International
Source:Eurekalert

Related biology news :

1. Singapore program to provide clinical insight; showcase for regional research
2. AADR awards 2010 Neal W. Chilton Fellowship in Clinical Research to Dolphus Dawson, III
3. Cell-enriched fat grafts improve long term graft retention in preclinical study
4. GenWay Clinical Laboratory receives accreditation from College of American Pathologists
5. UAB bone center director wins distinguished service award from clinical pathology society
6. TNO and Seventh Wave sign letter of intent on joint preclinical pharmaceutical outsourcing services
7. Magnetic nanotags spot cancer in mice earlier than methods now in clinical use
8. RadMD reaches 150th clinical trial
9. New cancer drug test promises safer and more effective clinical trials
10. IRSF announces funding of first clinical trial with disease-modifying therapy for Rett syndrome
11. General tumor marker test now offered by GenWay clinical laboratory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
(Date:6/27/2016)... Research and Markets has announced the addition of the "Biometrics ... The report forecasts the biometrics market ... CAGR of 12.28% during the period 2016-2020. The ... inputs from industry experts. The report covers the market landscape and ... a discussion of the key vendors operating in this market. ...
(Date:6/21/2016)... , June 21, 2016 NuData ... the new role of principal product architect and ... the director of customer development. Both will report ... technical officer. The moves reflect NuData,s strategic growth ... response to high customer demand and customer focus ...
Breaking Biology News(10 mins):
(Date:12/5/2016)... HAMILTON, Bermuda , Dec. 5, 2016 ... leading clinical-stage biopharmaceutical company focused on the treatment of ... of intepirdine for the treatment of Alzheimer,s disease will ... Disease (CTAD) Meeting on Friday, December 9, 2016 in ... CTAD will show results of both simple and complex ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... to soon resume cervical and lumbar disc production, company President, Jake Lubinski will ... who are implanting the AxioMed disc in Cologne and Karlsruhe to discuss the ...
(Date:12/5/2016)... NxGen MDx announced today that it brought its NxGen Informed ... been able to improve customer service through shortened turnaround times and at ... , CEO of NxGen MDx. ... A decrease in turnaround times by ... job opportunities at the Grand Rapid headquarters. The NxGen Informed ...
(Date:12/4/2016)... ... December 02, 2016 , ... A proposed five-year extension ... federally funded research and development is welcome news for the photonics community, say ... , As part of the National Defense Authorization Act (NDAA) compromise agreement finalized ...
Breaking Biology Technology: